You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens
|
|---|---|
| Published in |
Cancer Prevention Research, March 2011
|
| DOI | 10.1158/1940-6207.capr-10-0195 |
| Pubmed ID | |
| Authors |
Daniel W. Cramer, Robert C. Bast, Christine D. Berg, Eleftherios P. Diamandis, Andrew K. Godwin, Patricia Hartge, Anna E. Lokshin, Karen H. Lu, Martin W. McIntosh, Gil Mor, Christos Patriotis, Paul F. Pinsky, Mark D. Thornquist, Nathalie Scholler, Steven J. Skates, Patrick M. Sluss, Sudhir Srivastava, David C. Ward, Zhen Zhang, Claire S. Zhu, Nicole Urban |
| Abstract |
Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from 180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity when moving to phase III specimens that had been drawn within 6 months of the clinical diagnosis. Performance of all markers declined in phase III specimens more remote than 6 months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 3% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 150 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 36 | 23% |
| Student > Ph. D. Student | 24 | 15% |
| Other | 15 | 10% |
| Student > Bachelor | 15 | 10% |
| Student > Master | 14 | 9% |
| Other | 22 | 14% |
| Unknown | 30 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 28% |
| Agricultural and Biological Sciences | 34 | 22% |
| Biochemistry, Genetics and Molecular Biology | 17 | 11% |
| Chemistry | 7 | 4% |
| Immunology and Microbiology | 6 | 4% |
| Other | 16 | 10% |
| Unknown | 33 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2024.
All research outputs
#1,228,521
of 23,325,355 outputs
Outputs from Cancer Prevention Research
#130
of 1,378 outputs
Outputs of similar age
#4,737
of 110,014 outputs
Outputs of similar age from Cancer Prevention Research
#4
of 27 outputs
Altmetric has tracked 23,325,355 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,378 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 110,014 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.